C12N 2795/10011
Dsdna bacteriophages
Official title: dsDNA Bacteriophages
C12N2795/10011 (Dsdna bacteriophages) appears on 565 US grants and 816 published applications in this corpus.
Search patents in C12N- Granted patents
- 565
- Published applications
- 816
- Assignees
- 423
- Inventors
- 1,399
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 5 | 0 |
| 1996 | 6 | 0 |
| 1997 | 17 | 0 |
| 1998 | 14 | 0 |
| 1999 | 13 | 0 |
| 2000 | 10 | 0 |
| 2001 | 13 | 5 |
| 2002 | 15 | 12 |
| 2003 | 3 | 20 |
| 2004 | 12 | 21 |
| 2005 | 5 | 18 |
| 2006 | 6 | 11 |
| 2007 | 7 | 16 |
| 2008 | 8 | 11 |
| 2009 | 8 | 14 |
| 2010 | 8 | 24 |
| 2011 | 10 | 26 |
| 2012 | 17 | 19 |
| 2013 | 16 | 17 |
| 2014 | 12 | 24 |
| 2015 | 14 | 31 |
| 2016 | 25 | 37 |
| 2017 | 24 | 39 |
| 2018 | 19 | 35 |
| 2019 | 39 | 51 |
| 2020 | 29 | 51 |
| 2021 | 33 | 74 |
| 2022 | 37 | 79 |
| 2023 | 39 | 44 |
| 2024 | 33 | 58 |
| 2025 | 35 | 45 |
| 2026 | 17 | 34 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/10311SiphoviridaeIndexing code209
- C12N 2795/10111MyoviridaeIndexing code208
- C12N 2795/10211PodoviridaeIndexing code116
- C12N 2795/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code78
- C12N 2795/10041Use of virus, viral particle or viral elements as a vectorIndexing code46
- C12N 2795/10021Viruses as suchIndexing code29
- C12N 2795/10031Uses of virus other than therapeutic or vaccineIndexing code15
- C12N 2795/10032Use of virus as therapeutic agent, other than vaccineIndexing code12
All 15 subgroupsShow fewer
- C12N 2795/10051Methods of production or purification of viral materialIndexing code9
- C12N 2795/10033Use of viral protein as therapeutic agent other than vaccineIndexing code6
- C12N 2795/10071Demonstrated in vivo effectIndexing code4
- C12N 2795/10023Virus like particles [vlp]Indexing code3
- C12N 2795/10061Methods of inactivation or attenuationIndexing code3
- C12N 2795/10034Use of virus or viral component as vaccineIndexing code1
- C12N 2795/10088For redistributionIndexing code0
Recent patents
- Bacteriophage effective for controlling Salmonella typhimurium and its derived biofilm, and an antibacterial composition comprising the same6 Oct 2026US 12,751,982 B2Kyungpook National University Industry-Academic Cooperation Foundation
- Therapeutic bacteriophages22 Sep 2026US 12,742,158 B2University of Leicester
- Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder25 Aug 2026US 12,715,903 B2Palleon Pharmaceuticals Inc.
- Methods and systems for the rapid detection of Listeria using infectious agents28 Jul 2026US 12,692,482 B2Laboratory Corporation of America Holdings
- Methods for purifying bacteriophage and products of manufacture containing endotoxin-free bacteriophage preparations9 Jun 2026US 12,648,976 B2San Diego State University (SDSU) Foundation
- Methods and compositions for nucleic acid synthesis24 Sep 2026US 2026/0286415 A1Primrose Bio, Inc.
- Bacteriophages as a tool to manipulate gut commensal immune-modulation activity17 Sep 2026US 2026/0273002 A1Technion Research & Development Foundation Limited
- Peptide tags for phage imaging3 Sep 2026US 2026/0258373 A1The Regents of the University of California
- Bacteriophage(s) targeting capsular deficient klebsiella pneumoniae (kp), compositions comprising it(them) and use(s) thereof3 Sep 2026US 2026/0258374 A1
- Methods and compositions for conferring cellular resistance to viral infection3 Sep 2026US 2026/0258406 A1President and Fellows of Harvard College
Most cited
By later US patents
- Generation and selection of novel DNA-binding proteins and polypeptides293US 5,096,815 AProtein Engineering Corporation · 1992
- Generation and selection of novel DNA-binding proteins and polypeptides254US 5,198,346 AProtein Engineering Corporation · 1993
- Autocatalytic replication of recombinant RNA181US 4,786,600 AThe Trustees of Columbia University in the City of New York · 1988
- Ribonuclease resistant viral RNA standards180US 5,677,124 AAmbion, Inc. · 1997
- Preservation of viruses124US 5,149,653 AQuadrant Bioresources Limited · 1992